|
US1051350A
(en)
|
1910-02-02 |
1913-01-21 |
Thomas Nogier |
Apparatus for the sterilization of liquids.
|
|
DE4124942A1
(de)
|
1991-07-27 |
1993-01-28 |
Thomae Gmbh Dr K |
5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
|
|
CA2148931A1
(en)
|
1993-10-01 |
1995-04-13 |
Jurg Zimmermann |
Pyrimidineamine derivatives and processes for the preparation thereof
|
|
TW440563B
(en)
|
1996-05-23 |
2001-06-16 |
Hoffmann La Roche |
Aryl pyrimidine derivatives and a pharmaceutical composition thereof
|
|
ES2271283T3
(es)
|
2001-07-03 |
2007-04-16 |
Vertex Pharmaceuticals Incorporated |
Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
|
|
US7396940B2
(en)
|
2003-10-23 |
2008-07-08 |
Hoffmann-La Roche Inc. |
Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
|
|
EP1773807A2
(en)
|
2004-06-14 |
2007-04-18 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
EP1786813A2
(en)
|
2004-09-03 |
2007-05-23 |
Plexxikon, Inc. |
Bicyclic heteroaryl pde4b inhibitors
|
|
US7855205B2
(en)
|
2004-10-29 |
2010-12-21 |
Janssen Pharmaceutica Nv |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
|
GB0500492D0
(en)
|
2005-01-11 |
2005-02-16 |
Cyclacel Ltd |
Compound
|
|
EP1861382B1
(en)
|
2005-03-04 |
2012-10-10 |
Merck Sharp & Dohme Corp. |
Fused aromatic compounds having anti-diabetic activity
|
|
GB0520657D0
(en)
|
2005-10-11 |
2005-11-16 |
Ludwig Inst Cancer Res |
Pharmaceutical compounds
|
|
WO2007149427A2
(en)
|
2006-06-22 |
2007-12-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US20080119457A1
(en)
|
2006-08-24 |
2008-05-22 |
Serenex, Inc. |
Benzene, Pyridine, and Pyridazine Derivatives
|
|
CA2688187C
(en)
|
2007-05-07 |
2016-10-11 |
Merck & Co., Inc. |
Method of treament using fused aromatic compounds having anti-diabetic activity
|
|
JP2010031249A
(ja)
|
2008-06-23 |
2010-02-12 |
Sumitomo Chemical Co Ltd |
組成物及び該組成物を用いてなる発光素子
|
|
TWI546290B
(zh)
*
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
DE102008052943A1
(de)
*
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
CN101723936B
(zh)
|
2008-10-27 |
2014-01-15 |
上海睿星基因技术有限公司 |
激酶抑制剂及其在药学中的用途
|
|
EP2789615B1
(en)
|
2009-08-11 |
2017-05-03 |
Bristol-Myers Squibb Company |
Azaindazoles as Btk kinase modulators and use thereof
|
|
CN102625708A
(zh)
|
2009-09-09 |
2012-08-01 |
阿维拉制药公司 |
Pi3激酶抑制剂及其用途
|
|
KR101116234B1
(ko)
|
2009-10-29 |
2014-03-06 |
(주)퓨쳐켐 |
(3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
|
|
TW201219383A
(en)
|
2010-08-02 |
2012-05-16 |
Astrazeneca Ab |
Chemical compounds
|
|
JP5809279B2
(ja)
|
2010-10-14 |
2015-11-10 |
ジェイダブリュ ファーマセウティカル コーポレーション |
リバースターン類似体の新規な化合物およびその製造方法と用途
|
|
KR20130133051A
(ko)
|
2011-03-16 |
2013-12-05 |
에프. 호프만-라 로슈 아게 |
6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
|
|
WO2012126181A1
(en)
|
2011-03-24 |
2012-09-27 |
Ying Luo |
Use of kinase inhibitors in preventing and treating inflammatory disorder
|
|
JP5427321B2
(ja)
|
2011-07-27 |
2014-02-26 |
アストラゼネカ アクチボラグ |
２−（２，４，５−置換−アニリノ）ピリミジン化合物
|
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
|
US20150087628A1
(en)
|
2012-04-10 |
2015-03-26 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
CN103508961B
(zh)
|
2012-06-26 |
2015-07-22 |
中美冠科生物技术（太仓）有限公司 |
抗肿瘤药物
|
|
US9738610B2
(en)
|
2012-09-24 |
2017-08-22 |
Whitehead Institute For Biomedical Research |
Indazole derivatives and uses thereof
|
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
HRP20182128T1
(hr)
|
2012-11-21 |
2019-02-08 |
Janssen Biotech, Inc. |
Bispecifična egfr/c-met protutijela
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
BR112015027114B1
(pt)
|
2013-04-29 |
2021-12-21 |
Chong Kun Dang Pharmaceutical Corp |
Compostos inibidores seletivos de histona desacetilase e seu uso
|
|
US20180057603A1
(en)
|
2013-08-09 |
2018-03-01 |
The Trustees Of The University Of Pennsylvania |
Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
|
|
MX370588B
(es)
|
2013-08-30 |
2019-12-16 |
Ptc Therapeutics Inc |
Inhibidores de la bmi-1 de pirimidina sustituida.
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
CN106232625B
(zh)
|
2013-10-01 |
2020-04-24 |
免疫医疗有限公司 |
治疗和诊断过表达α-V-β-6的癌症的方法
|
|
GB201400034D0
(en)
|
2014-01-02 |
2014-02-19 |
Astrazeneca Ab |
Pharmaceutical Compositions comprising AZD9291
|
|
CN104761544B
(zh)
|
2014-01-03 |
2019-03-15 |
北京轩义医药科技有限公司 |
Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
|
|
WO2015112705A2
(en)
|
2014-01-24 |
2015-07-30 |
Clovis Oncology, Inc. |
Therapeutic combinations for treating cancer
|
|
WO2015127234A1
(en)
|
2014-02-20 |
2015-08-27 |
Board Of Regents, The University Of Texas System |
Use of ibrutinib to treat egfr mutant cancer
|
|
CN104860941B
(zh)
*
|
2014-02-25 |
2017-03-22 |
上海海雁医药科技有限公司 |
2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
|
|
CN104876914B
(zh)
|
2014-02-28 |
2017-04-19 |
山东轩竹医药科技有限公司 |
嘧啶衍生物类间变性淋巴瘤激酶抑制剂
|
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
|
CN104892585B
(zh)
|
2014-03-06 |
2018-07-03 |
山东轩竹医药科技有限公司 |
嘧啶衍生物类间变性淋巴瘤激酶抑制剂
|
|
MX369111B
(es)
|
2014-04-04 |
2019-10-29 |
Astrazeneca Ab |
Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.
|
|
EP3489232A3
(en)
*
|
2014-04-04 |
2019-07-31 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2015175965A1
(en)
|
2014-05-15 |
2015-11-19 |
The Research Foundation For Suny |
Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
|
|
CN111875585B
(zh)
|
2014-06-12 |
2023-06-23 |
上海艾力斯医药科技股份有限公司 |
一类激酶抑制剂
|
|
JP6230205B2
(ja)
*
|
2014-06-19 |
2017-11-15 |
アリアド ファーマシューティカルズ， インコーポレイテッド |
キナーゼ阻害のためのヘテロアリール化合物
|
|
CN105254615B
(zh)
|
2014-07-11 |
2017-02-22 |
杭州华东医药集团新药研究院有限公司 |
苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
|
|
SG11201610777VA
(en)
|
2014-07-11 |
2017-01-27 |
Genmab As |
Antibodies binding axl
|
|
CN105315285B
(zh)
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
WO2016024185A1
(en)
|
2014-08-12 |
2016-02-18 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
CN104140418B
(zh)
|
2014-08-15 |
2016-08-24 |
常州润诺生物科技有限公司 |
2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
|
|
WO2016023822A1
(en)
|
2014-08-15 |
2016-02-18 |
Boehringer Ingelheim International Gmbh |
Afatinib pharmaceutical kit for cancer treatment
|
|
CN106458969A
(zh)
|
2014-08-25 |
2017-02-22 |
四川海思科制药有限公司 |
一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
|
|
JPWO2016032003A1
(ja)
|
2014-08-30 |
2017-07-13 |
国立大学法人金沢大学 |
肺癌患者用治療剤及び肺癌患者治療の有効性の予測検査方法
|
|
CA2959716A1
(en)
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Anti-her3 antibodies and uses of same
|
|
WO2016038610A1
(en)
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
|
|
US20170190788A1
(en)
|
2014-09-11 |
2017-07-06 |
Bulldog Pharmaceuticals, Inc. |
Uses of anti-her3 antibodies for treating cancer
|
|
EP3198030B1
(en)
|
2014-09-26 |
2020-11-04 |
HI-STEM gGmbH Im Deutschen Krebsforschungszentrum DKFZ |
Novel methods for sub-typing and treating cancer
|
|
CN105461695B
(zh)
|
2014-09-29 |
2018-03-27 |
齐鲁制药有限公司 |
嘧啶或三嗪衍生物及其制备方法和用途
|
|
CN105237515B
(zh)
|
2014-10-10 |
2018-06-05 |
益方生物科技（上海）有限公司 |
氘代嘧啶类化合物、其制备方法、药物组合物和用途
|
|
CN111170999B
(zh)
|
2014-10-11 |
2023-06-30 |
上海翰森生物医药科技有限公司 |
Egfr抑制剂及其制备和应用
|
|
RS66529B1
(sr)
|
2014-10-13 |
2025-03-31 |
Yuhan Corp |
Jedinjenja i kompozicije za modulaciju aktivnosti egfr mutant kinaze
|
|
US10308648B2
(en)
|
2014-10-16 |
2019-06-04 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
CN111170998B
(zh)
|
2014-11-05 |
2023-04-11 |
益方生物科技(上海)股份有限公司 |
嘧啶或吡啶类化合物、其制备方法和医药用途
|
|
CN114224894B
(zh)
|
2014-12-03 |
2025-01-07 |
奥克兰联合服务有限公司 |
用于治疗癌症的激酶抑制剂前药
|
|
MX382869B
(es)
|
2014-12-11 |
2025-03-13 |
Beta Pharma Inc |
Derivados de 2-anilinopirimidina sustituida como moduladores de egfr.
|
|
PL3236943T3
(pl)
|
2014-12-24 |
2023-05-29 |
Principia Biopharma Inc. |
Kompozycje do krętniczo-czczego dostarczania leków
|
|
WO2016112302A1
(en)
|
2015-01-09 |
2016-07-14 |
Metastat, Inc. |
Method of predicting sensitivity of tumor cell growth to combination therapy of fgfr inhibitor
|
|
US20180271853A1
(en)
|
2015-01-09 |
2018-09-27 |
Metastat, Inc. |
Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variant III
|
|
AU2016216253B2
(en)
|
2015-02-04 |
2019-11-21 |
Beyondbio Inc. |
Heterocyclic compound and pharmaceutical composition comprising same
|
|
JP2018504418A
(ja)
|
2015-02-05 |
2018-02-15 |
ティルノーヴォ リミテッド |
癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ
|
|
CN104961731A
(zh)
|
2015-02-05 |
2015-10-07 |
苏州晶云药物科技有限公司 |
一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
|
|
CN105985323A
(zh)
|
2015-02-15 |
2016-10-05 |
宁波文达医药科技有限公司 |
新型表皮生长因子受体抑制剂及其应用
|
|
US20180087114A1
(en)
|
2015-03-05 |
2018-03-29 |
Trovagene, Inc. |
Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluid
|
|
CN106138061B
(zh)
|
2015-04-03 |
2019-06-04 |
中国人民解放军第三军医大学第三附属医院 |
预防或减弱肺纤维化的复合物及其制剂和用途
|
|
CN106138020A
(zh)
|
2015-04-03 |
2016-11-23 |
中国人民解放军第三军医大学第三附属医院 |
双胍类药物在制备预防或减弱肺纤维化的药物中的应用
|
|
WO2016164217A1
(en)
|
2015-04-09 |
2016-10-13 |
Clovis Oncology, Inc. |
Therapeutic combinations for treating cancer
|
|
CN104844580B
(zh)
|
2015-04-17 |
2017-10-20 |
中国药科大学 |
嘧啶类化合物、其制备方法及医药用途
|
|
SG11201708556SA
(en)
|
2015-04-23 |
2017-11-29 |
Medimmune Ltd |
Combination therapy for non-small cell lung cancer positive for egfr mutation
|
|
CN104817541B
(zh)
|
2015-05-11 |
2017-06-16 |
苏州东南药业股份有限公司 |
一种抗肿瘤药物的合成方法
|
|
CN108012529A
(zh)
|
2015-05-15 |
2018-05-08 |
诺华股份有限公司 |
治疗egfr突变的癌症的方法
|
|
RS62809B1
(sr)
|
2015-05-21 |
2022-02-28 |
Chemocentryx Inc |
Modulatori ccr2
|
|
US20180117053A1
(en)
|
2015-05-27 |
2018-05-03 |
Metastat, Inc. |
The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
|
|
WO2016197012A1
(en)
|
2015-06-03 |
2016-12-08 |
Orient Pharma Inc. |
Methods and compositions for treating non-small cell lung cancer
|
|
US20160355503A1
(en)
|
2015-06-04 |
2016-12-08 |
Cleave Biosciences, Inc. |
NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX
|
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
CN104910049B
(zh)
|
2015-06-16 |
2016-06-29 |
苏州明锐医药科技有限公司 |
Azd9291中间体及其制备方法
|
|
HRP20200551T1
(hr)
|
2015-07-10 |
2020-07-10 |
Genmab A/S |
Axl-specifični konjugati protutijelo-lijek za liječenje raka
|
|
EP3325662B1
(en)
|
2015-07-17 |
2023-08-30 |
Pacylex Pharmaceuticals Inc. |
Epigenetic silencing of nmt2
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
US10550112B2
(en)
|
2015-07-20 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Pyrimidines as EGFR inhibitors and methods of treating disorders
|
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
|
US10561646B2
(en)
|
2015-07-24 |
2020-02-18 |
Shanghai Haiyan Pharmaceutical Technology Co. Ltd. |
EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
|
|
CN105001208A
(zh)
|
2015-08-06 |
2015-10-28 |
南京雷科星生物技术有限公司 |
一种表皮生长因子受体egfr抑制剂及其制备方法与用途
|
|
US10980765B2
(en)
|
2015-08-14 |
2021-04-20 |
Board Of Supervisors Of Louisiana State University |
Isothiocyanatostilbenes as a novel method and product for treating cancer
|
|
CN105153122B
(zh)
|
2015-08-27 |
2018-07-20 |
上海圣考医药科技有限公司 |
[(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
|
|
CN106478605A
(zh)
|
2015-09-02 |
2017-03-08 |
上海页岩科技有限公司 |
嘧啶类化合物、其制备方法和医药用途
|
|
CN105126125A
(zh)
|
2015-09-12 |
2015-12-09 |
复旦大学 |
一种氧化锌-钆-药物复合纳米粒子及其制备方法和应用
|
|
ES2956642T3
(es)
|
2015-09-25 |
2023-12-26 |
Dizal Jiangsu Pharmaceutical Co Ltd |
Compuestos y métodos para la inhibición de JAK
|
|
AU2016343517B2
(en)
|
2015-10-19 |
2020-04-30 |
Sunshine Lake Pharma Co., Ltd. |
A salt of EGFR inhibitor, crystalline form and uses thereof
|
|
US20170115275A1
(en)
|
2015-10-23 |
2017-04-27 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
|
|
US10093668B2
(en)
|
2015-10-28 |
2018-10-09 |
Northwestern University |
Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)
|
|
WO2017079267A1
(en)
|
2015-11-02 |
2017-05-11 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
CN106674202A
(zh)
|
2015-11-05 |
2017-05-17 |
惠州信立泰药业有限公司 |
化合物a的二甲磺酸盐及其晶型和含有该盐的药物组合物
|
|
CN106699736A
(zh)
|
2015-11-17 |
2017-05-24 |
惠州信立泰药业有限公司 |
化合物A甲磺酸盐的晶型γ和含有该晶型的药物组合物
|
|
CN105294717B
(zh)
|
2015-11-18 |
2017-12-22 |
乳源瑶族自治县大众药品贸易有限公司 |
一种egfr抑制剂的盐、晶型及其用途
|
|
CN105461729B
(zh)
|
2015-11-18 |
2017-12-05 |
乳源瑶族自治县大众药品贸易有限公司 |
一种egfr抑制剂的盐、晶型及其用途
|
|
RU2603960C1
(ru)
|
2015-11-19 |
2016-12-10 |
Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") |
Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака
|
|
RU2606949C9
(ru)
|
2015-11-19 |
2018-03-14 |
ЗАО "Р-Фарм" |
Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
|
|
CN105348267A
(zh)
|
2015-12-01 |
2016-02-24 |
中山奕安泰医药科技有限公司 |
合成azd9291中间体的方法
|
|
CN108289895B
(zh)
|
2015-12-03 |
2021-07-20 |
浙江尖峰亦恩生物科技有限公司 |
噻吩并嘧啶衍生物及其用途
|
|
AU2016362394B2
(en)
|
2015-12-03 |
2021-01-14 |
Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. |
Heterocycle compounds and uses thereof
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
TWI623316B
(zh)
|
2015-12-22 |
2018-05-11 |
Taiho Pharmaceutical Co Ltd |
Antitumor effect enhancer derived from pyrrolopyrimidine compound
|
|
CN105601620A
(zh)
|
2015-12-25 |
2016-05-25 |
北京康立生医药技术开发有限公司 |
一种甲磺酸迈瑞替尼的制备方法
|
|
EP3394047B1
(en)
|
2015-12-27 |
2019-12-11 |
Neuform Pharmaceuticals, Inc. |
Deuterated compounds for treating cancer and compositions and methods thereof
|
|
CN106928150B
(zh)
|
2015-12-31 |
2020-07-31 |
恩瑞生物医药科技（上海）有限公司 |
丙烯酰胺苯胺衍生物及其药学上的应用
|
|
WO2017120429A1
(en)
|
2016-01-07 |
2017-07-13 |
CS Pharmasciences, Inc. |
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
|
|
CN108779091B
(zh)
|
2016-01-08 |
2022-12-27 |
欧利瑟斯制药公司 |
色烯化合物和第二活性剂的组合
|
|
JP7068173B2
(ja)
|
2016-01-08 |
2022-05-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
カーゴ送達のための、脂質二重層コーティングを備えたメソ多孔性シリカナノ粒子
|
|
CN105646454B
(zh)
|
2016-01-19 |
2018-05-08 |
浙江大学 |
含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用
|
|
TWI745345B
(zh)
|
2016-02-01 |
2021-11-11 |
瑞典商阿斯特捷利康公司 |
製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
MX2021009540A
(es)
|
2016-02-04 |
2022-12-14 |
Auransa Inc |
Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia.
|
|
US11116767B2
(en)
|
2016-02-04 |
2021-09-14 |
Pharmaengine, Inc. |
3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications
|
|
CN105777716B
(zh)
|
2016-02-25 |
2018-04-10 |
清华大学 |
一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
|
|
CN105585557B
(zh)
|
2016-02-25 |
2018-06-22 |
清华大学 |
用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
|
|
US10513509B2
(en)
|
2016-05-26 |
2019-12-24 |
Recurium Ip Holdings, Llc |
EGFR inhibitor compounds
|
|
CN105886648A
(zh)
|
2016-06-06 |
2016-08-24 |
武汉海吉力生物科技有限公司 |
用于检测egfr基因t790m突变的试剂盒
|
|
CN106366022B
(zh)
|
2016-08-19 |
2018-03-13 |
上海工程技术大学 |
一种用于制备azd9291的中间体及其制备方法和应用
|
|
CN106366072B
(zh)
|
2016-08-19 |
2018-12-07 |
上海工程技术大学 |
一种azd9291的制备方法
|
|
CN106397407B
(zh)
|
2016-08-31 |
2018-09-04 |
浙江科聚化工有限公司 |
抗肿瘤药物azd9291衍生物的制备方法
|
|
CN106432231B
(zh)
|
2016-09-09 |
2018-06-12 |
无锡佰翱得生物科学有限公司 |
Azd9291的药用盐、及其晶型和制备方法
|
|
CN106565522A
(zh)
|
2016-09-29 |
2017-04-19 |
福格森（武汉）生物科技股份有限公司 |
一种由氟代芳香化合物制备烷氧基芳香化合物的方法
|
|
CN106496196B
(zh)
|
2016-10-20 |
2019-07-02 |
南京雷科星生物技术有限公司 |
一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
|
|
CN106543060B
(zh)
|
2016-10-31 |
2018-11-06 |
湖南欧亚药业有限公司 |
一种奥斯替尼甲磺酸盐的制备方法
|
|
CN106668866A
(zh)
|
2017-02-13 |
2017-05-17 |
江苏省中医药研究院 |
一种抗非小细胞肺癌的药物组合物及其应用
|
|
CN106883216B
(zh)
|
2017-04-06 |
2020-03-13 |
张家港威胜生物医药有限公司 |
一种奥希替尼的制备方法
|